Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally
We recently compiled a list of the These 10 Firms Dominated Last Week’s Rally. In this article, we are going to take a look ...
pharmaphorum23h
FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt
After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...
UroToday23h
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday14h
SUO 2024: Adjuvant Radiation Following Cystectomy: Underutilized Therapy?
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to an Advanced Disease and Adjuvant Therapy session. Dr. Omar Mian discussed the role of adjuvant ...